Andrew N. Cornforth

C4 Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

17h-index788citations53works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(41), Cancer Immunotherapy and Biomarkers(24), CAR-T cell therapy research(22), Cancer Research and Treatments(10), vaccines and immunoinformatics approaches(6)

Publications53 total

An NLRP3-stimulatory adjuvant improves the immunogenicity of influenza virus vaccines in mice and non-human primates
mBio·2025Open Access
Abstract 3552: An mRNA-encoded adjuvant-enzyme activates STING to enhance the immunogenicity of vaccines targeting human papillomavirus positive cancers
Cancer Research·2025
1163 A unique dendritic cell activation state utilizes inflammasomes to stimulate memory T cell responses in humans
Regular and Young Investigator Award Abstracts·2022Open Access
1172 A unique dendritic cell activation states utilizes inflammasomes to stimulate anti-tumor immunity in mice
Regular and Young Investigator Award Abstracts·2022Open Access
Abstract 893: A chimeric PD1-CD28 switch receptor enhances the activity of TRuC-T cells
Cancer Research·2020
Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
Oncotarget·2019· 5 citedOpen Access
Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines
Cancer Research·2019
Abstract 1357: Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines
Clinical Research (Excluding Clinical Trials)·2019
Patient-Specific Dendritic Cell Vaccines with Autologous Tumor Antigens in 72 Patients with Metastatic Melanoma
Melanoma Management·2019· 17 citedOpen Access
Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.
Journal of Clinical Oncology·2019
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
Journal for ImmunoTherapy of Cancer·2018· 71 citedOpen Access
Dendritic Cell Vaccines for Melanoma: Past, Present and Future
Melanoma Management·2016· 26 cited
Abstract CT105: Randomized trial of dendritic vs tumor cell patient-specific vaccines: 5-year analysis
Cancer Research·2016· 1 cited
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
Journal for ImmunoTherapy of Cancer·2015Open Access
Abstract 4845: Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma
Cancer Research·2015
Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).
Journal of Clinical Oncology·2015· 2 cited
Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B‐positive patients with hepatocellular carcinoma
Journal of Surgical Oncology·2015· 34 citedOpen Access
Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B positive patients with hepatocellular carcinoma
2015
Phase III randomized, double-blinded, placebo-controlled multicenter trial of Eltrapuldencel-T: autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in GM-CSF in patients with metastatic melanoma
2015
Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.
PubMed·2015· 15 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Robert O. Dillman(31), Carol DePriest(10), Lisheng Ge(9), Martin R. Jadus(9), Denysha Carbonell(8), Patric M. Schiltz(6), Edward F. McClay(6), Gabriel I. Nistor(6), Neil Hoa(6), Michael Bayer(5), Gabriel Nistor(5), Shankar K. Nayak(5), Thomas Amatruda(4), Senthamil R. Selvan(4), Carol A. Kruse(4), Nils Lambrecht(4), Yi Ouyang(4), Maria Dacosta-Iyer(4), Cheryl Mayorga(3), Xiaojin Wang(3)